论文部分内容阅读
目的 制备抗人尿激酶受体单克隆抗体，为今后ｕＰＡＲ 病理生理作用及临床意义的研究提供新的手段。方法 利用杂交瘤技术，用经ＰＭＡ刺激的Ｕ９３７ 细胞与可溶性尿激酶受体（ｓｕＰＡＲ）免疫Ｂａｌｂ／ｃ 小鼠，与ＳＰ２／０ 细胞融合。结果 获得国内第１ 组４ 株抗人尿激酶受体（ｕＰＡＲ）单抗，分别命名为ＳＺ－ ９８、ＳＺ－ ９９ 、ＳＺ－ １００ 、ＳＺ－ １０１。结论 ４ 株单抗均能与ｕＰＡＲ 特异性结合，能与Ｕ９３７ 细胞及经ＰＭＡ作用的Ｋ５６２ 细胞反应。ＳＺ－ １０１ 与国外抗ｕＰＡＲ单抗３９３６ 有相同的ｕＰＡＲ 结合位点；而ＳＺ－９８、ＳＺ－ ９９ 与ＳＺ－ １００ 在ｕＰＡＲ上有不同的结合位点
Objective To prepare anti-human urokinase receptor monoclonal antibody for the future pathological and physiological role of uPAR and provide a new means of clinical significance. Methods Hybridoma technique was used to immunize Balb / c mice with PMA-stimulated U937 cells and soluble urokinase receptor (suPAR) and fused with SP2 / 0 cells. Results The first group of domestic monoclonal antibody against human urokinase receptor (uPAR) was obtained and named as SZ-98, SZ-99, SZ-100 and SZ-101 respectively. Conclusion All four mAbs can specifically bind to uPAR and react with U937 cells and PMA-treated K562 cells. SZ-101 and foreign anti-uPAR mAb 3936 have the same uPAR binding sites; while SZ-98, SZ-99 and SZ-100 have different binding sites on uPAR